18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Immune Response Measuring Increased Numbers of Peptide Specific T Cells as Calculated by the Tetramer Assay.Primary· Screening through week 21
Immune response measuring increased numbers of peptide specific T cells as calculated by the tetramer assay. The numbers of Peptide Specific T Cells are reported as the percent of CD8+ T cells that were p/HLA multimer positive for each antigen.
Antigen A3-1, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Subject 4
0
Antigen A3-2, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Subject 4
0
Antigen A3-3, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Subject 4
0
Antigen A3-4, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Subject 4
0
Antigen A3-5, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Subject 4
0
Antigen A3-6, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Subject 4
0
Antigen A3-7, screening
Group
Value
95% CI
Subject 1
0
Subject 3
0
Antigen B8-1, screening
Group
Value
95% CI
Subject 1
0
Safety and Tolerability of the Mature Dendritic Cell Vaccine (mDC3/8 Vaccines).Primary· End of Study visit (10-28 days after last DC vaccine)
Safety endpoint is type and number of adverse events. Tolerability endpoint is subject's completion or withdrawal from study treatment.
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
3
Mature Dendritic Cell (DC) Vaccine
2
Clinical Response to the mDC3/8 Vaccine(s)Secondary· At the End of Study Treatment visit (~10-28 Days after the last DC vaccine)
using RECIST 1.1
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
2
Mature Dendritic Cell (DC) Vaccine
3
Time to Progression Post-mDC3/8 Vaccine AdministrationSecondary· Up to 30 weeks after the first mDC3/8 Vaccine
based on RECIST 1.1 criteria, until occurrence of a censoring event
Subject 1
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
113
Subject 2
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
NA
Subject 3
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
NA
Subject 4
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
NA
Subject 5
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
80
Safety and Side Effect Profile of the Dendritic Cell Vaccine (mDC3/8 Vaccines) Administered to Patients Given After a Single Dose of Cyclophosphamide.Secondary· End of Study visit (10-28 days after last DC vaccine)
Assessed through collection of Adverse Events.
Group
Value
95% CI
Mature Dendritic Cell (DC) Vaccine
5
Adverse events — posted to ClinicalTrials.gov
Time frame: Collection of AEs will begin at the time of the first apheresis procedure (Apheresis #1) and continue until subject discontinuation or the End of Study Visit. (week 30)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Mature Dendritic Cell (DC) Vaccine
Serious: 1/5 (20%)
Deaths: 0/5
Serious adverse events (2 terms)
Reaction
System
Mature Dendritic Cell (DC)…
Tumor pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Surgical and medical procedures - Other (Palliative mass resection)
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception
· recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it
· Phase 1
· recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
· Phase 2
· recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT
· NA
· recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve
· NA
· recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
· EARLY_PHASE1
· not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD
· NA
· not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm
· Phase 2
· not yet recruiting
NCT07463131 — Negative Income Tax Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092453.